Severity of COVID-19 in hospitalized patients with and without atopic disease
© 2021 The Authors..
BACKGROUND: Data from the 2009 influenza pandemic suggested asthma might protect from severe disease in hospitalized patients. Asthma does not appear to increase risk for hospitalization or mortality with COVID-19.
OBJECTIVE: This study was undertaken to see if atopy actually protected those hospitalized with COVID-19.
METHODS: Retrospective chart review on all patients testing positive for SARS-CoV-2 over 2 months at a major adult and pediatric tertiary referral center hospital. Charts were evaluated for history of atopic disease, as were the need for ICU admission, requirement for supplemental oxygen and/or intubation, and in hospital mortality.
RESULTS: No significant differences in outcomes for patients (n = 275) based on atopic disease were noted: ICU admission, 43% versus 44.7% (atopic versus no atopic disease, respectively; p = 0.84); supplemental oxygen use, 79.1% versus 73.6% (p = 0.36); intubation rate, 35.8% versus 36.5% (p = 0.92); and mortality rate, 13.4% versus 20.7% (p = 0.19). More patients with atopic disease had COPD listed as a diagnosis in their chart (38.8% versus 17.3%, p < 0.001). COPD was associated with an increased rate of ICU admission (aOR = 2.22 (1.15, 4.30) p = 0.02) and intubation (aOR = 2.05 (1.07, 3.92) p = 0.03). After adjusting for COPD, patients with atopic disease had a trend for reduced mortality (aOR 0.55 (0.23, 1.28), p = 0.16), but those with asthma did not (p > 0.2).
CONCLUSION: Severity of COVID-19 in hospitalized patients does not differ based on atopic status. However, adjusting for presence of COPD led to a suggestion of possible reduced severity in patients with atopy but not asthma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
The World Allergy Organization journal - 14(2021), 2 vom: 09. Feb., Seite 100508 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Timberlake, Dylan T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.waojou.2021.100508 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320812871 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320812871 | ||
| 003 | DE-627 | ||
| 005 | 20231225174423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.waojou.2021.100508 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320812871 | ||
| 035 | |a (NLM)33520082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Timberlake, Dylan T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severity of COVID-19 in hospitalized patients with and without atopic disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a BACKGROUND: Data from the 2009 influenza pandemic suggested asthma might protect from severe disease in hospitalized patients. Asthma does not appear to increase risk for hospitalization or mortality with COVID-19 | ||
| 520 | |a OBJECTIVE: This study was undertaken to see if atopy actually protected those hospitalized with COVID-19 | ||
| 520 | |a METHODS: Retrospective chart review on all patients testing positive for SARS-CoV-2 over 2 months at a major adult and pediatric tertiary referral center hospital. Charts were evaluated for history of atopic disease, as were the need for ICU admission, requirement for supplemental oxygen and/or intubation, and in hospital mortality | ||
| 520 | |a RESULTS: No significant differences in outcomes for patients (n = 275) based on atopic disease were noted: ICU admission, 43% versus 44.7% (atopic versus no atopic disease, respectively; p = 0.84); supplemental oxygen use, 79.1% versus 73.6% (p = 0.36); intubation rate, 35.8% versus 36.5% (p = 0.92); and mortality rate, 13.4% versus 20.7% (p = 0.19). More patients with atopic disease had COPD listed as a diagnosis in their chart (38.8% versus 17.3%, p < 0.001). COPD was associated with an increased rate of ICU admission (aOR = 2.22 (1.15, 4.30) p = 0.02) and intubation (aOR = 2.05 (1.07, 3.92) p = 0.03). After adjusting for COPD, patients with atopic disease had a trend for reduced mortality (aOR 0.55 (0.23, 1.28), p = 0.16), but those with asthma did not (p > 0.2) | ||
| 520 | |a CONCLUSION: Severity of COVID-19 in hospitalized patients does not differ based on atopic status. However, adjusting for presence of COPD led to a suggestion of possible reduced severity in patients with atopy but not asthma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Atopy | |
| 650 | 4 | |a CDC, Centers for Disease Control and Prevention | |
| 650 | 4 | |a COPD, Chronic Obstructive Pulmonary Disease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19, Coronavirus Disease 2019 | |
| 650 | 4 | |a CRP, C Reactive Peptide | |
| 650 | 4 | |a Hospitalization | |
| 650 | 4 | |a ICS, Inhaled corticosteroid | |
| 650 | 4 | |a ICU, Intensive Care Unit | |
| 650 | 4 | |a Il-6, Interleukin 6 | |
| 650 | 4 | |a LABA, Long acting beta agonist | |
| 650 | 4 | |a NHANES, National Health and Nutrition Examination Survey | |
| 650 | 4 | |a RAST, Radioallergosorbent test | |
| 650 | 4 | |a RT-PCR, Real time polymerase chain reaction | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a Severity | |
| 700 | 1 | |a Narayanan, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Ogbogu, Princess U |e verfasserin |4 aut | |
| 700 | 1 | |a Raveendran, Rekha |e verfasserin |4 aut | |
| 700 | 1 | |a Porter, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Scherzer, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Prince, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Grayson, Mitchell H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The World Allergy Organization journal |d 2008 |g 14(2021), 2 vom: 09. Feb., Seite 100508 |w (DE-627)NLM19437937X |x 1939-4551 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:2 |g day:09 |g month:02 |g pages:100508 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.waojou.2021.100508 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 2 |b 09 |c 02 |h 100508 | ||